Metraipolis › archive › dc_afc19718e166

Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis — Europe PMC PMID:41573536

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41573536
DOI
10.3389/fimmu.2025.1659650
License (as archived)
solo-consultazione
Archived
2026-11-07T00:38:37.096Z
SHA-256 of the archived text
597040b9e3d76508697aecb4c800a8237b0c34f02e54722f51e73eebcb1c6217
Stable URL of this page
https://metraipolis.com/documento/dc_afc19718e166

How to cite

Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis — Europe PMC PMID:41573536 — Europe PMC (en), https://europepmc.org/article/MED/41573536 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_afc19718e166 (Metraipolis archive dc_afc19718e166, sha256 597040b9e3d76508697aecb4c800a8237b0c34f02e54722f51e73eebcb1c6217)
BibTeX
@misc{dcafc19718e166,
  title = {Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis — Europe PMC PMID:41573536},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41573536},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_afc19718e166; sha256 597040b9e3d76508697aecb4c800a8237b0c34f02e54722f51e73eebcb1c6217},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41573536. Agents can read the archived copy with the MCP tool read_document.